Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $14,100.00 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Arnold M. Baskies bought 5,000 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was acquired at an average cost of $2.82 per share, for a total transaction of $14,100.00. Following the purchase, the director now owns 120,000 shares in the company, valued at approximately $338,400. This trade represents a 4.35 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Anixa Biosciences Price Performance

Anixa Biosciences stock opened at $2.94 on Friday. The firm’s fifty day moving average price is $2.74 and its 200 day moving average price is $3.05. The company has a market capitalization of $94.66 million, a price-to-earnings ratio of -7.54 and a beta of 0.90. Anixa Biosciences, Inc. has a 12-month low of $2.07 and a 12-month high of $4.70.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. Analysts forecast that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Anixa Biosciences

A number of hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in Anixa Biosciences during the 3rd quarter valued at $34,000. Westside Investment Management Inc. lifted its position in shares of Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the last quarter. Tyler Stone Wealth Management grew its stake in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares in the last quarter. Finally, International Assets Investment Management LLC increased its holdings in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after buying an additional 23,800 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on ANIX shares. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, January 22nd.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.